TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
RNAssist CEO Andrew Goldsborough will attend the RNA Vaccines and Therapeutics Conference in London, 23–24 September 2025, to share TheraPHIX™, a stabilisation technology enabling RNA vaccines and therapeutics to be stored as liquids at ambient temperatures. Connect with Andrew during the event to discuss your projects and the future of RNA medicines.
Dr Andrew Goldsborough will be presenting "TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines" at 15:45 on 12th June 2025
Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™! We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, *"TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines"* will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.
We are delighted to announce our sponsorship
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com